Developing a laboratory model of Wilms tumour to test potential new treatments
In vitro modelling of MYCN-driven poor prognosis Wilms' tumour for assessment of novel therapies
In vitro modelling of MYCN-driven poor prognosis Wilms' tumour for assessment of novel therapies
Understanding neuroblastoma heterogeneity: genetic studies of circulating neuroblastoma tumour cells
In vitro evaluation of the potential of glucose restriction as an adjuvant therapy for paediatric brain tumours
Investigations into EVI1 mediated epigenetic modulation in childhood leukaemia
Defining the cellular origins of neonatal and paediatric brain tumours
Identifying the metabolic ‘Achilles Heel’ of childhood brain cancers
Identification of new drug targets to improve treatment options and reduce treatment-related toxicity for children diagnosed with aggressive B-cell non-Hodgkin lymphoma (B-NHL)
Brain distribution models to select polymer-delivered drugs for the treatment of childhood brain cancers
Circulating molecular biomarkers for earlier identification of high risk Wilms tumour
Screening for novel drug combinations in childhood B-cell acute lymphoblastic leukaemia